We are delighted to announce that Eagle IP has been recognized once more by IAM Patent 1000 - The World's Leading Patent Professionals - as a top ranked, “Highly Recommended Firm in Patent Prosecution”.

The IAM Patent 1000 is a respected annual directory dedicated to identifying leading patent firms and individual practitioners globally. Published by Intellectual Asset Management (IAM), the guide covers key jurisdictions and evaluates capabilities across the core areas of patent law. Inclusion in the directory is determined by a rigorous, independent research process that includes 900+ extensive interviews with in-house counsel, patent attorneys, and industry experts.

According to IAM, Eagle IP has carved out “a distinctive reputation for far-reaching and highly sophisticated patent protection” and “a prime pick for life sciences companies, research institutions and technology-driven enterprises navigating complex international patent strategies.”

IAM has further highlighted five individuals from our firm: Our President and Managing Director, Ms. Jennifer Che, Principal Ms. Yolanda Wang, Principal Ms. Pauli Wong, Dr. Jacqueline C Lui, Dr. Ho Chung Lui.

We are incredibly honoured to be included in this highest category among a select group of Hong Kong’s top IP firms. We are deeply grateful to IAM for this recognition of our work. At Eagle IP, we are dedicated to providing exceptional service to our clients by drawing upon our hands-on knowledge of US, Chinese, and Hong Kong patent laws, our proven ability to craft sophisticated and creative patent strategies, and our strong technical expertise. We will continue to build upon these strengths to deliver the highest level of service and support to the innovators who entrust us with protecting their groundbreaking ideas.

As always, a huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

我们的过去活动

Recommended Insights

No More Hindsight Bias: China’s Supreme People's Court Reins in Patent Inventiveness Assessments

2026年6月25日
For foreign applicants navigating patent litigation or invalidation in China, a common frustration is hindsight bias. Too often, CNIPA or lower courts strip down a patent into isolated technical features, find those features across disparate prior art references, and declare the invention to be "obvious". To counter such hindsight reasoning, the core criterion has always […]

A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

2026年2月27日
Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process. The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the […]

Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment

2020年7月10日
Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]

China Releases Draft Examination Guidelines for the new Patent Law

2020年12月4日
The Chinese Patent Office (CNIPA) is moving forward at breakneck speeds aiming to get all the necessary pieces in place for the June 1, 2021 date when the new 4th Amendment of the Patent Law will come into effect. Most recently, this means a flurry of drafts coming out from CNIPA, including, but not limited […]
Top crossarrow-right